News Image

While growth is established for NASDAQ:CORT, the stock's valuation remains reasonable.

By Mill Chart

Last update: Jan 24, 2024

Our stock screener has singled out CORCEPT THERAPEUTICS INC (NASDAQ:CORT) as an attractive growth opportunity. NASDAQ:CORT is demonstrating remarkable growth potential while maintaining strong financial indicators, making it a reasonably priced option. We'll explore this further.

What does the Growth looks like for NASDAQ:CORT

Every stock receives a Growth Rating from ChartMill, ranging from 0 to 10. This rating assesses various growth aspects, including historical and projected EPS and revenue growth. NASDAQ:CORT boasts a 7 out of 10:

  • Measured over the past years, CORT shows a quite strong growth in Earnings Per Share. The EPS has been growing by 15.94% on average per year.
  • Looking at the last year, CORT shows a quite strong growth in Revenue. The Revenue has grown by 13.20% in the last year.
  • Measured over the past years, CORT shows a very strong growth in Revenue. The Revenue has been growing by 20.35% on average per year.
  • CORT is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 23.26% yearly.
  • Based on estimates for the next years, CORT will show a quite strong growth in Revenue. The Revenue will grow by 15.07% on average per year.
  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.

How do we evaluate the Valuation for NASDAQ:CORT?

ChartMill assigns a Valuation Rating to every stock. This score ranges from 0 to 10 and evaluates the different valuation aspects and compares the price to earnings and cash flows, while taking into account profitability and growth. NASDAQ:CORT scores a 5 out of 10:

  • Based on the Price/Earnings ratio, CORT is valued cheaply inside the industry as 82.76% of the companies are valued more expensively.
  • Based on the Price/Forward Earnings ratio, CORT is valued cheaper than 80.30% of the companies in the same industry.
  • 79.80% of the companies in the same industry are more expensive than CORT, based on the Enterprise Value to EBITDA ratio.
  • Compared to the rest of the industry, the Price/Free Cash Flow ratio of CORT indicates a rather cheap valuation: CORT is cheaper than 87.19% of the companies listed in the same industry.
  • The excellent profitability rating of CORT may justify a higher PE ratio.
  • CORT's earnings are expected to grow with 18.68% in the coming years. This may justify a more expensive valuation.

Understanding NASDAQ:CORT's Health Score

ChartMill employs a unique Health Rating system for all stocks. This rating, ranging from 0 to 10, is determined by analyzing various liquidity and solvency ratios. For NASDAQ:CORT, the assigned 8 for health provides valuable insights:

  • CORT has an Altman-Z score of 13.76. This indicates that CORT is financially healthy and has little risk of bankruptcy at the moment.
  • The Altman-Z score of CORT (13.76) is better than 91.13% of its industry peers.
  • There is no outstanding debt for CORT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
  • CORT has a Current Ratio of 3.54. This indicates that CORT is financially healthy and has no problem in meeting its short term obligations.
  • CORT has a Quick Ratio of 3.48. This indicates that CORT is financially healthy and has no problem in meeting its short term obligations.

A Closer Look at Profitability for NASDAQ:CORT

ChartMill assigns a Profitability Rating to every stock. This score ranges from 0 to 10 and evaluates the different profitability ratios and margins, both absolutely, but also relative to the industry peers. NASDAQ:CORT scores a 8 out of 10:

  • Looking at the Return On Assets, with a value of 15.39%, CORT belongs to the top of the industry, outperforming 95.57% of the companies in the same industry.
  • CORT has a better Return On Equity (19.80%) than 92.61% of its industry peers.
  • CORT has a Return On Invested Capital of 18.44%. This is amongst the best in the industry. CORT outperforms 94.58% of its industry peers.
  • Measured over the past 3 years, the Average Return On Invested Capital for CORT is significantly above the industry average of 16.66%.
  • The last Return On Invested Capital (18.44%) for CORT is well below the 3 year average (23.51%), which needs to be investigated, but indicates that CORT had better years and this may not be a problem.
  • CORT's Profit Margin of 20.31% is amongst the best of the industry. CORT outperforms 94.58% of its industry peers.
  • CORT has a better Operating Margin (21.82%) than 90.15% of its industry peers.
  • Looking at the Gross Margin, with a value of 98.64%, CORT belongs to the top of the industry, outperforming 97.04% of the companies in the same industry.

More Affordable Growth stocks can be found in our Affordable Growth screener.

Our latest full fundamental report of CORT contains the most current fundamental analsysis.

Disclaimer

This is not investing advice! The article highlights some of the observations at the time of writing, but you should always make your own analysis and invest based on your own insights.

Back

CORCEPT THERAPEUTICS INC

NASDAQ:CORT (4/23/2024, 1:10:59 PM)

23.725

+1.43 (+6.39%)

CORT News

News Imagea day ago - Market News VideoNotable Monday Option Activity: RIOT, SIG, CORT
News Imagea day ago - Corcept Therapeutics IncorporatedCorcept Announces Positive Results From Open-Label Portion of Pivotal Phase 3 GRACE Trial in Patients With Cushing’s Syndrome
News Image4 days ago - ChartmillWhile growth is established for NASDAQ:CORT, the stock's valuation remains reasonable.

For those who appreciate growth without the sticker shock, CORCEPT THERAPEUTICS INC (NASDAQ:CORT) is worth considering.

News Image8 days ago - Corcept Therapeutics IncorporatedCorcept Completes Enrollment in Phase 2 DAZALS Trial in Patients With Amyotrophic Lateral Sclerosis (ALS)
News Image8 days ago - Corcept Therapeutics IncorporatedCorcept Completes Enrollment in Phase 2 DAZALS Trial in Patients With Amyotrophic Lateral Sclerosis (ALS)

MENLO PARK, Calif., April 15, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the...

News Image15 days ago - Corcept Therapeutics IncorporatedCorcept Completes Enrollment in Pivotal Phase 3 Rosella Trial of Relacorilant in Patients With Platinum-Resistant Ovarian Cancer
News Image22 days ago - Corcept Therapeutics IncorporatedCorcept Completes Enrollment in Phase 3 Gradient Trial of Relacorilant in Patients With Adrenal Cushing’s Syndrome
News Image22 days ago - Corcept Therapeutics IncorporatedCorcept Completes Enrollment in Phase 3 Gradient Trial of Relacorilant in Patients With Adrenal Cushing’s Syndrome

MENLO PARK, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the...

News Imagea month ago - Market News VideoNotable Monday Option Activity: GME, LULU, CORT
News Image2 months ago - Seeking AlphaCorcept Therapeutics GAAP EPS of $0.28 beats by $0.02, revenue of $135.4M beats by $6.1M (NASDAQ:CORT)

Corcept Therapeutics reports Q4 2023 financial results, with GAAP EPS of $0.28 beating expectations by $0.02 and revenue of $135.4M surpassing estimates by...

News Image2 months ago - Corcept Therapeutics IncorporatedCorcept Therapeutics Announces Fourth Quarter and Full-Year 2023 Audited Financial Results and Provides Corporate Update
News Image2 months ago - Corcept Therapeutics IncorporatedCorcept Therapeutics Announces Fourth Quarter and Full-Year 2023 Audited Financial Results and Provides Corporate Update

MENLO PARK, Calif., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the...

CORT Links
Follow us for more